Anika Therapeutics (ANIK) Equity Average: 2011-2025
Historic Equity Average for Anika Therapeutics (ANIK) over the last 14 years, with Sep 2025 value amounting to $147.2 million.
- Anika Therapeutics' Equity Average fell 24.53% to $147.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 24.53%. This contributed to the annual value of $183.1 million for FY2024, which is 26.43% down from last year.
- Anika Therapeutics' Equity Average amounted to $147.2 million in Q3 2025, which was down 0.54% from $148.0 million recorded in Q2 2025.
- Anika Therapeutics' Equity Average's 5-year high stood at $288.6 million during Q4 2021, with a 5-year trough of $147.2 million in Q3 2025.
- In the last 3 years, Anika Therapeutics' Equity Average had a median value of $209.4 million in 2024 and averaged $209.0 million.
- Its Equity Average has fluctuated over the past 5 years, first rose by 4.34% in 2022, then slumped by 30.84% in 2024.
- Over the past 5 years, Anika Therapeutics' Equity Average (Quarterly) stood at $288.6 million in 2021, then dropped by 1.15% to $285.2 million in 2022, then fell by 15.38% to $241.4 million in 2023, then slumped by 30.84% to $166.9 million in 2024, then dropped by 24.53% to $147.2 million in 2025.
- Its Equity Average stands at $147.2 million for Q3 2025, versus $148.0 million for Q2 2025 and $151.2 million for Q1 2025.